Transgenic mouse models to study the role of APOE in hyperlipidemia and atherosclerosis

Atherosclerosis

Volumn 137, Issue 1, 1998, Pages 1-11

  Hofker, Marten H ^a   Van Vlijmen, Bart J m ^b   Havekes, Louis M ^b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b TNO   (Netherlands)

Author keywords

APOE; Apolipoprotein; Cholesterol; Gene targeting; Lipoprotein; Triglyceride

Indexed keywords

APOLIPOPROTEIN C1; APOLIPOPROTEIN E; VERY LOW DENSITY LIPOPROTEIN;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROGENESIS; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CHOLESTEROL TRANSPORT; FOAM CELL; GENE THERAPY; GENE TRANSFER; HYPERLIPIDEMIA; LIPOLYSIS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

ANIMALS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; DISEASE MODELS, ANIMAL; HUMANS; HYPERLIPIDEMIAS; MICE; MICE, TRANSGENIC;

EID: 0032478347     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00266-9     Document Type: Review

References (83)

1. Lusis A.J. Genetic factors affecting blood lipoproteins: the candidate gene approach. J Lipid Res. 29:1988;397-429.
2. Roberts A., Thompson J.S. Inbred mice and their hypbrids as an animal model for atherosclerosis research. Adv Exp Med Biol. 67:1976;313-327.
3. Nishina P.M., Verstuyft J., Paigen B. Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res. 31:1990;859-869.
4. De Knijff P., Havekes L.M. Apolipoprotein E as a risk factor for coronary heart disease: a genetic and molecular biology approach. Curr Opin Lipid. 7:1996;59-63.
5. Wardell M.R., Weisgraber K.H., Havekes L.M., Rall S.C. Jr. Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121-127. J Biol Chem. 264:1989;21205-21210.
6. Van den Maagdenberg A.M.J.M., De Knijff P., Stalenhoef A.F.H., Gevers Leuven J.A., Havekes L.M., Frants R.R. Apolipoprotein E3Leiden allele results from a partial gene duplication in exon 4. Biochem Biophys Res Commun. 165:1989;851-857.
7. Ghiselli G., Schaefer E.J., Gascon P., Breser H.B. Jr. Type III hyperlipoproteinemia associated with apolipoprotein E deficiency. Science. 214(4526):1981;1239-1241.
8. Rajavashisth T.B., Kaptein J.S., Reue K.L., Lusis A.J. Evolution of apolipoprotein E: mouse sequence and evidence for an 11-nucleotide ancestral unit. Proc Natl Acad Sci USA. 82:1985;8085-8089.
9. Hoffer M.J.V., Hofker M.H., Van Eck M.M., Havekes L.M., Frants R.R. Evolutionary conservation of the mouse apolipoprotein e-c1-c2 gene cluster: Structure and genetic variablity in inbred mice. Genomics. 15:1993;62-67.
10. Van Eck M.M., Hoffer M.J.V., Havekes L.M., Frants R.R., Hofker M.H. The apolipoprotein C2-linked (Acl) gene: A new gene within the mouse apolipoprotein e-c1-c2 gene cluster. Genomics. 21:1994;110-115.
11. Allan C.M., Walker D., Segrest J.P., Taylor J.M. Identification and characterization of a new human gene (APOC4) in the apolipoprotein E, C-I, and C-II gene locus. Genomics. 28:1995;291-300.
12. Li W.-H., Tanimura M., Luo C.-C., Datta S., Chan L. The apolipoprotein multigene family: biosynthesis, structure-function relationships, and evolution. J Lipid Res. 29:1988;245-271.
13. De Silva H.V., Lauer S.J., Wang J., Simonet W.S., Weisgraber K.H., Mahley R.W., Taylor J.M. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem. 269:1994;2324-2335.
14. Ito Y., Azrolan N., O'Connell A., Walsh A., Breslow J.L. Hypertriglyceridemia as a result of human apoCIII gene expression in transgenic mice. Science. 249:1990;790-793.
15. Shachter N.S., Hayek T., Leff T., Smith J.D., Rosenberg D.W., Walsh A., Ramakrishnan R., Goldberg I.J., Ginsberg H.N., Breslow J.L. Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. J Clin Invest. 93:1994;1683-1690.
16. Jong M.C., Dahlmans V.E.H., Van Gorp P.J.J., Willems van Dijk K., Breuer M.L., Hofker M.H., Havekes L.M. In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J Clin Invest. 98(10):1996;2259-2267.
17. Allan C.M., Taylor J.M. Expression of a novel human apolipoprotein (apoc IV) causes hypertriglyceridemia in transgenic mice. J Lipid Res. 37(7):1996;1510-1518.
18. Piedrahita J.A., Zhang S.H., Hagaman J.R., Oliver P.M., Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA. 89:1992;4471-4475.
19. Plump A.S., Smith J.D., Hayek T., Aalto-Setälä K., Walsh A., Rubin E.M., Breslow J. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:1992;343-353.
20. Van Ree J.H., Van den Broek W.J.A.A., Dahlmans V.E.H., Groot P.H.E., Vidgeon-Hart M., Frants R.R., Wieringa B., Havekes L.M., Hofker M.H. Diet-induced hypercholesterolemia and atherosclerosis in heterozygous apolipoprotein E-deficient mice. Atherosclerosis. 111:1994;25-37.
21. Zhang S.H., Reddick R.L., Burkey B., Maeda N. Diet-induced atherosclerosis in mice heterozygous and homozygous for apolipoprotein E gene disruption. J Clin Invest. 94:1994;937-945.
22. Paigen B., Holmes P., Mitchel D., Albee D. Comparison of atherosclerotic lesions and HDL-lipid levels in male, female and testosterone-treated female mice from strains C57BL/6, BALB/c, and C3H. Atherosclerosis. 64:1987;215-221.
23. Rensen P.C.N., Van Berkel T.J.C. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo. J Biol Chem. 271(25):1996;14791-14799.
24. Simonet W.S., Bucay N., Lauer S.J., Wirak D.O., Stevens M.E., Weisgraber K.H., Pitas R.E., Taylor J.M. In the absence of a downstream element, the apolipoprotein E gene is expressed at high levels in kidneys of transgenic mice. J Biol Chem. 265:1990;10809-10812.
25. Smith J.D., Plump A.S., Hayek T., Walsh A., Breslow J.L. Accumulation of human apolipoprotein E in the plasma of transgenic mice. J Biol Chem. 265:1990;14709-14712.
26. Simonet W.S., Bucay N., Pitas R.E., Lauer S.J., Taylor J.M. Multiple tissue specific elements control the apolipoprotein E/CI Gene locus in transgenic mice. J Biol Chem. 266:1991;8651-8654.
27. Shachter N.S., Zhu Y., Walsh A., Breslow J.L., Smith J.D. Localization of a liver-specific enhancer in the apolipoprotein E/C-I/C-II gene locus. J Lipid Res. 34:1993;1699-1707.
28. Simonet W.S., Bucay N., Lauer S.J., Taylor J.M. A far-downstream hepatocyte-specific control region directs expression of the linked human apolipoprotein E and C-I genes in transgenic mice. J Biol Chem. 268:1993;8221-8229.
29. Allan C.M., Walker D., Taylor J.M. Evolutionary duplication of a hepatic control region in the human apolipoprotein E gene locus - Identification of a second region that confers high level and liver-specific expression of the human apolipoprotein E gene in transgenic mice. J Biol Chem. 270:1995;26278-26281.
30. Gu H., Zou Y.R., Rajewsky K. Independent control of immunoglobulin switch recombination at individual switch regions evidenced through Cre-loxP-mediated gene targeting. Cell. 73(6):1993;1155-1164.
31. De Knijff P., Van den Maagdenberg A.M.J.M., Stalenhoef A.F.H., Gevers Leuven J.A., Demacker P.N.M., Kuyt L.P., Frants R.R., Havekes L.M. Familial Dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigenerational pedigree. J Clin Invest. 88:1991;643-655.
32. Rall S.C. Jr., Newhouse Y.M., Clarke H.R.G., Weisgraber K.H., McCarthy B.J., Mahley R.W., Bersot T.P. Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3/3; structure and genetics of an apolipoprotein E variant. J Clin Invest. 83:1989;1095-1101.
33. Van den Maagdenberg A.M.J.M., Hofker M.H., Krimpenfort P.J.A., De Bruijn I., Van Vlijmen B., Van der Boom H., Havekes L.M., Frants R.R. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem. 268:1993;10540-10545.
34. Van Vlijmen B.J.M., Willems van Dijk K., Van't Hof H.B., Van Gorp P.J.J., Van der Zee A., Van der Boom H., Breuer M.L., Hofker M.H., Havekes L.M. In the absence of endogenous mous apolipoprotein E, apolipoprotein E2(Arg-158→Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E3leiden transgenic mice. J Biol Chem. 271(48):1996;30595-30602.
35. Jong M.C., Dahlmans V.E.H., Van Gorp P.J.J., Breuer M.L., Mol M.J.T.M., Van der Zee A., Frants R.R., Hofker M.H., Havekes L.M. Both lipolysis and hepatic uptake of vldl are impaired in transgenic mice coexpressing human apolipoprotein E3leiden and human apolipoprotein C1. Arterioscler Thromb Vasc Biol. 16(8):1996;934-940.
36. Fazio S., Lee Y.-L., Ji Z.-S., Rall S.C. Jr. Type III hyperlipoproteinemic phenotype in transgenic mice expressing dysfunctional apolipoprotein E. J Clin Invest. 92:1993;1497-1503.
37. Fazio S., Horie Y., Simonet W.S., Weisgraber K.H., Taylor J.M., Rall S.C. Jr. Altered lipoprotein metabolism in transgenic mice expressing low levels of a human receptor-binding-defective apolipoprotein E variant. J Lipid Res. 35:1994;408-416.
38. Huang Y., Schwendner S.W., Rall S.C. Jr., Mahley R.W. Hypolipidemic and hyperlipidemic phenotypes in transgenic mice expressing human apolipoprotein E2. J Biol Chem. 271(46):1997;29146-29151.
39. Willnow T.E., Sheng Z., Ishibashi S., Herz J. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science. 264(5164):1994;1471-1474.
40. Shimano H., Yamada N., Shimada M., Ohsawa N., Fukazawa C., Yazaki Y., Takaku F., Katsuki M. Hepatic and renal expression of rat apolipoprotein E under control of the metallothionein promoter in transgenic mice. Biochim Biophys Acta Lipids Lipid Metab. 1090:1991;91-94.
41. Shimano H., Yamada N., Katsuki M., Shimada M., Gotoda T., Harada K., Murase T., Fukazawa C., Takaku F., Yazaki Y. Overexpression of apolipoprotein E in transgenic mice: marked reduction in plasma lipoproteins except high density lipoprotein and resistance against diet-induced hypercholesterolemia. Proc Natl Acad Sci USA. 89:1992;1750-1754.
42. Shimano H., Yamada N., Katsuki M., Yamamoto K., Gotoda T., Harada K., Shimada M., Yazaki Y. Plasma lipoprotein metabolism in transgenic mice overexpressing apolipoprotein E; accelerated clearance of lipoproteins containing apoB. J Clin Invest. 90:1992;2084-2091.
43. Kowal R.C., Herz J., Weisgraber K.H., Mahley R.W., Brown M.S., Goldstein J.L. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J Biol Chem. 263:1990;10771-10779.
44. Shachter N.S., Ebara T., Ramakrishnan R., Steiner G., Breslow J.L., Ginsberg H.N., Smith J.D. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein ci. J Clin Invest. 98(3):1996;846-855.
45. Masucci-Magoulas L., Goldberg I.J., Bisgaier C.L., Serajuddin H., Francone O.L., Breslow J.L., Tall A.R. A mouse model with features of familial combined hyperlipidemia. Science. 275(5298):1997;391-394.
46. Van Vlijmen B.J.M., Van't Hof H.B., Mol M.J.T.M., Van der Boom H., Van der Zee A., Frants R.R., Hofker M.H., Havekes L.M. Modulation of very low density lipoprotein production and clearance contributes to age- and gender-dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice. J Clin Invest. 97:1996;1184-1192.
47. Van Ree J.H., Van den Broek W.J.A.A., Van der Zee A., Dahlmans V.E.H., Wieringa B., Frants R.R., Havekes L.M., Hofker M.H. Inactivation of Apoe and Apoc1 by two consecutive rounds of gene targeting: effects on mRNA expression levels of gene cluster members. Hum Mol Genet. 4:1995;1403-1409.
48. Nakashima Y., Plump A.S., Raines E.W., Breslow J.L., Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 14:1994;133-140.
49. Reddick R.L., Zhang S.H., Maeda N. Atherosclerosis in mice lacking apoE: Evaluation of lesional development and progression. Arterioscler Thromb. 14:1994;141-147.
50. Zhang S.H., Reddick R.L., Piedrahita J.A., Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258:1992;468-471.
51. Tangirala R.K., Rubin E.M., Palinski W. Quantitation of atherosclerosis in murine models: Correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J Lipid Res. 36:1995;2320-2328.
52. Van Vlijmen B.J.M., Van den Maagdenberg A.M.J.M., Gijbels M.J.J., Van der Boom H., HogenEsch H., Frants R.R., Hofker M.H., Havekes L.M. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest. 93:1994;1403-1410.
53. Fazio S., Sanan D.A., Lee Y.-L., Ji Z.-S., Mahley R.W., Rall S.C. Jr. Susceptibility to diet-induced atherosclerosis in transgenic mice expressing a dysfunctional human apolipoprotein E(Arg 112,Cys142). Arterioscler Thromb. 14:1994;1873-1879.
54. Groot P.H.E., Van Vlijmen B.J.M., Benson G.M., Hofker M.H., Schiffelers R., Vidgeonhart M., Havekes L.M. Quantitative assessment of aortic atherosclerosis in APOE3Leiden transgenic mice and its relationship to serum cholesterol exposure. Arterioscler Thromb Vasc Biol. 16(8):1996;926-933.
55. Mortimer B.-C., Redgrave T.G., Spangler E.A., Verstuyft J.G., Rubin E.M. Effect of human ApoE4 on the clearance of chylomicron-like lipid emulsions and atherogenesis in transgenic mice. Arterioscler Thromb. 14:1994;1542-1552.
56. Palinski W., Ord V.A., Plump A.S., Breslow J.L., Steinberg D., Witztum J.L. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb. 14:1994;605-616.
57. Palinski W., Tangirala R.K., Miller E., Young S.G., Witztum J.L. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol. 15:1995;1569-1576.
58. Leppanen P, Luoma J, Hofker MH, Havekes LM, Ylä-Herttuala S. Characterization of atherosclerotic lesions in apoE3Leiden transgenic mice: Expression of scavenger receptors and low density lipoprotein receptor-related protein and the presence of oxidized low density lipoproteins in early and advanced atherosclerotic lesions. Atherosclerosis 1998;136:147-52.
59. Kodama T., Freeman M., Rohrer L., Zabrecky J., Matsudaira P., Krieger M. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature. 343(6258):1990;531-535.
60. Hendriks W.L., van der Sman-de Beer F., Van Vlijmen B.J.M., Van Vark L.C., Hofker M.H., Havekes L.M. Uptake by J774 macrophages of very-low-density lipoproteins isolated from apoE-deficient mice is mediated by a distinct receptor and stimulated by lipoprotein lipase. Arterioscler Thromb Vasc Biol. 17:1997;498-504.
61. Smith J.D., Trogan E., Ginsberg M., Grigaux C., Tian J., Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA. 92:1995;8264-8268.
62. Qiao J., Tripathi J., Mishra N.K., Cai Y., Tripathi S., Wang X.P., Imes S., Fishbein M.C., Clinton S., Libby P.et al. Role of macrophage colony stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol. 150(5):1997;1687-1699.
63. Dansky H.M., Charlton S., Harper M.M., Smith J.D. T and B lymphocytes play a minor sole in atherosclerotic plaque formation in the apolipoprotein E deficient mouse. Proc Natl Acad Sci USA. 94(9):1997;4642-4646.
64. Fyfe A.I., Qiao J.-H., Lusis A.J. Immune-deficient mice develop typical atherosclerotic fatty streaks when fed an atherogenic diet. J Clin Invest. 94:1994;2516-2520.
65. Von Eckardstein A. Cholesterol efflux from macrophages and other cells. Curr Opin Lipid. 7:1996;308-319.
66. Mazzone T. Apolipoprotein E secretion by macrophages: its potential physiological functions. Curr Opin Lipid. 7:1996;303-307.
67. Bellosta S., Mahley R.W., Sanan D.A., Murata J., Newland D.L., Taylor J.M., Pitas R.E. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J Clin Invest. 96:1995;2170-2179.
68. Shimano H., Ohsuga J., Shimada M., Namba Y., Gotoda T., Harada K., Katsuki M., Yazaki Y., Yamada N. Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall. J Clin Invest. 95:1995;469-476.
69. Van Ree J.H., Gijbels M.J.J., Van den Broek W.J.A.A., Hofker M.H., Havekes L.M. Atypical xanthomatosis in apolipoprotein E-deficient mice after cholesterol feeding. Atherosclerosis. 112:1995;237-243.
70. Feingold K.R., Elias P.M., Man M.-Q., Fartasch M., Zhang S.H., Maeda N. Apolipoprotein E deficiency leads to cutaneous foam cell formation in mice. J Invest Dermatol. 104:1995;246-250.
71. Linton M.F., Atkinson J.B., Fazio S. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science. 267:1995;1034-1037.
72. Boisvert W.A., Spangenberg J., Curtiss L.K. Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation. J Clin Invest. 96:1995;1118-1124.
73. Fazio S., Babaev V.R., Murray A.B., Hasty A.H., Carter K.J., Gleaves L.A., Atkinson J., Linton M.F. Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophages. Proc Natl Acad Sci USA. 94(9):1997;4647-4652.
74. Stevenson S.C., Marshall-Neff J., Teng B., Lee C.B., Roy S., McClelland A. Phenotypic correction of hypercholesterolemia in ApoE-deficient mice by adenovirus-mediated in vivo gene transfer. Arterioscler Thromb. 15:1995;479-484.
75. Kashyap V.S., Santamarina-Fojo S., Brown D.R., Parrott C.L., Applebaum-Bowden D., Meyn S., Talley G., Paigen B., Maeda N., Brewer H.B. Jr. Apolipoprotein E deficiency in mice: Gene replacement and prevention of atherosclerosis using adenovirus vectors. J Clin Invest. 96:1995;1612-1620.
76. Li Q., Kay M.A., Finegold M., Stratford-Perricaudet L.D., Woo S.L.C. Assessment of recombinant adenoviral vectors for hepatic gene therapy. Hum Gene Ther. 4:1993;403-409.
77. Herz J., Gerard R.D. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA. 90:1993;2812-2816.
78. Tsukamoto K., Smith P., Glick J.M., Rader D.J. Liver directed gene transfer and prolonged expression of three major human apoe isoforms in apoe deficient mice. J Clin Invest. 100(1):1997;107-114.
79. Sullivan P.M., Mezdour H., Aratani Y., Knouff C., Najib J., Reddick R.L., Quarfordt S.H., Maeda N. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet induced hypercholesterolemia and atherosclerosis. J Biol Chem. 272(29):1997;17972-17980.
80. Pászty C., Maeda N., Verstuyft J., Rubin E.M. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest. 94:1994;899-903.
81. Suzuki H., Kurihara Y., Takeya M., Kamada N., Kataoka M., Jishage K., Ueda O., Sakaguchi H., Higashi T., Suzuki T.et al. A role for the macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 386(6622):1997;292-296.
82. Paigen B., Mitchel D., Reue K., Morrow A., Lusis A.J., LeBoeuf R.C. Ath-1, a gene determining atherosclerosis susceptibility and high density lipoprotein levels in mice. Proc Natl Acad Sci USA. 84:1987;3763-3767.
83. Purcell-Huynh D.A., Weinreb A., Castellani L.W., Mehrabian M., Doolittle M.H., Lusis A.J. Genetic factors in lipoprotein metabolism - Analysis of a genetic cross between inbred mouse strains NZB/BINJ and SM/J using a complete linkage map approach. J Clin Invest. 96:1995;1845-1858.